Intellectual Property Acquisition Opportunity

On behalf of the Administrator, Stephen Cork of Cork Gully LLP, Hilco Streambank is seeking offers to acquire the intellectual property of Oxtex Limited (in Administration) (“Oxtex” or the “Company”).

Spun-out from the University of Oxford in 2011, Oxtex was a medical device company that developed and manufactured anisotropic self-inflating tissue expanders for use in human, dental and animal health.

Oxtex raised around £6.2m in equity funding during its lifetime and achieved commercialisation of its Animal healthcare product, Expaniderm. The Company’s was also developing two human health products, Qantex, a self-controlled tissue expander previously filed for CE-marking, and Cleara-Talk, a nasal obturator - yet to undergo proof of concept study.

Intellectual Property relating to a number of medical products and their supporting core platform technology are available for sale.


Friday 28 February 2020 @ Noon GMT


Tissue Expansion is a major unmet need

Skin and tissue damage can result from conditions such as tumour and skin cancer excision, plastic and cosmetic surgery, congenital abnormalities, or acquired tissue defects. Creating sufficient skin and tissue for repair of open wounds post-surgery is not straightforward in either humans or animals. Although external skin-grafts are used in many hospitals, they can prove problematic to apply and are often costly. In veterinary care, skin-grafting is seldom undertaken.

Tissue expansion approaches offer a more elegant solution to skin and tissue damage. Tissue expansion devices are currently widely used in reconstructive plastic surgery to generate new skin and soft tissue for a variety of indications, including breast reconstruction and scar revision surgery. These devices traditionally operate using silicone balloon-type tissue expanders, however because of this are often too bulky for the reconstruction of delicate anatomic features (such as the nose), and in addition their isotropic (i.e. multi-directional) expansion can cause complications.

Expansion is achieved through regular (typically weekly) percutaneous injections of sterile saline solution that gradually inflate the balloon over a period of approximately two to three months.

These expansion injections can be painful – especially in children – and are usually performed by a doctor, which can be both expensive and inconvenient as it requires multiple visits to the clinic or hospital.

Repeated percutaneous inflation is often poorly tolerated by patients and can be associated with higher infection risks. There is a significant unmet need in both human and animal medicine for an in vivo expansion device that can inflated autonomously and in a controlled way, to facilitate tissue expansion.

Oxtex - Products

Oxtex was developing a range of intelligent tissue expansion devices for use in human (with the aim of progressing to support dental health) and had commercialised a lead product for the veterinary medicine market. Rather than repeated percutaneous inflation, like the products of their competitors, Oxtex’s devices used an autonomous gradual continuous expansion method that was expected to cause less discomfort than traditional balloon expansion, and was of greater convenience for both patients and surgeons.

Oxtex’s devices are:

  • The first in a new class of implantable soft-tissue expanders
  • Self-filling, negating the need for repeated clinical visits
  • Delayed in their onset of action, facilitating incisional wound healing
  • Available in a range of size (veterinary) and development of cuboid shape (human) for various surgical needs
  • Constructed from tried and tested materials used in human implants

In human health, the Company forecast the total Autonomous Controlled Tissue Expander market (non-breast) over the next ten years to grow to c. 2.5 million patients annually, anticipated by the Company’s management to be an opportunity in the region of £45 million by 2028 (at circa 20% market penetration).

Expaniderm – More than 1200 devices commercialised and used

Expaniderm is the company’s lead veterinary product and has been developed to facilitate tissue expansion for surgical cases in which there is an insufficiency for optimal wound reconstruction. More than 1,200 devices had been used in various animals including dogs, horses and cats, and around 90% of veterinary customers report being satisfied with the Expaniderm product. Launched in 2018 and a new product to the veterinary market, Expaniderm generated more than £21,000 of sales in the first eight months of 2019, and repeat custom was increasing. The Company had forecast and anticipated sales nearing £300,000 during 2020.

Screenshot 2019-11-14 at 16.20.07

Qantex – Oxtex’s Lead Product in Human Health

Oxtex have developed a first in class autonomous anisotropic controlled tissue expander that has a number of uses (once adapted for anatomical location) for human health purposes, including reconstruction surgery, scar/burn revisions, dental surgery, oral cleft (cleft lip, cleft lip and palate, or isolated cleft palate) and craniofacial surgery, congenital anophthalmia correction, excision of congenital naevi, syndactyly (fused digit) correction, and acute compartment syndrome requiring fasciotomy.

In 2014, Qantex received Bio Medical Catalyst funding for furthering the human device development of the devices which ultimately resulted in a Medical Device Directive application for a CE-mark in 2018. Further information was requested from the Notified Body as a result of this application where after the CE mark was not awarded. Subsequently in 2019 the company submitted a further (late stage) Biomedical Catalyst application for a porcine and human trial.

Screenshot 2019-11-14 at 17.04.04

Cleara-Talk – A novel device for velopharyneal dysfunction

In conjunction with Salisbury NHS, Oxtex had developed a nasal obturator, a device placed in the nostrils to prevent nasal escape of air during speech. This device could benefit patient groups that experience velopharyneal dysfunction (e.g. cleft palate, cerebral palsy, brain injuries, multiple sclerosis and ENT oncological cases). The product operates by using a valve mechanism that results is a slightly hyponasal or ‘cul-de-sac’ vocal resonance (quality of voice) generally considered to be more acceptable, less effortful and easier for others to understand. The device had been intended to be CE-marked in 2019. In the UK and USA alone, the Company expected the market for Cleara-Talk to reach up to 7 million patients by 2028. Oxtex had calculated that this would result in an annual addressable market in the UK and USA in the region of £100 million by 2028.

Screenshot 2019-11-14 at 17.04.48

Available Assets

Clinical Data

Clinical Data supporting the R&D is available, consisting of:

  • In vitro testing scenarios for the Qantex device development iterations
  • In vivo porcine study data for a precursor version of the Qantex device
  • Clinical data from veterinary user


The company has a portfolio of five patent families that cover its products under development, in addition to a drafted priority filing covering an early stage hydrogel product for dental application.

A patent schedule is available to download here.

Technical Documentation / Proprietary Know-How

Substantial technical documentation and proprietary Know-How are available in the form of trade secrets, including Regulatory Documentation surrounding Oxtex’s CE-mark application of Qantex, and clinical data supporting Clerea Talk, and clinical data supporting the use and commercialisation of Expaniderm.

Trade Marks

Oxtex has a suite of trade marks protecting the Oxtex corporate brand, in addition to the Expaniderm, Qantex and Cleara Talk product brands.

A trade mark schedule is available to download here.

Goodwill in the Company’s brand


The Company is likely to have generated goodwill in its Expaniderm product brand.

Domain Names and Copyright in Web Content

The Company’s created a number of sites at the oxtex.com, clearatalk.com and expaniderm.com domains, which contain information around its corporate brand and products.

Sale Process

Offers are due Friday 28 February 2020 @ Noon GMT.

Please contact Hilco Streambank to obtain an NDA and for more information regarding the sale process. A Bid Submission Form is available on request.

Key Terms & Conditions

The bidder acknowledges that Hilco acts as an agent for the Joint Administrators who offer for sale only what right, title and interest (if any) the Company possesses in the assets. The information provided has not been verified by Hilco and bidders are deemed to have carried out their own due diligence.

VAT at 20% will be added to the price if applicable. Legal completion to occur within 5 business days of bid acceptance. Hilco Streambank's full Terms and Conditions apply. 

Contact Us

For further information about the sale process please contact the following Hilco Streambank representatives:

Interested Parties

Hilco Global will only use data you have agreed to share with us. You have the ability to view, change and delete data at any time upon request. Please view our privacy policy.